

1 **Foot-and-mouth disease virus-like particle mRNA vaccine induces strong**
2 **humoral and cellular immunity**

3 Haiyun Liu¹, Yun Zhang¹, Suyu Mu¹, Fengping Hou³, LiXin Jiang¹, Zi Wang¹, Hu Dong¹, Muhammad
4 Muntazir Mehdi¹, Huichen Guo^{1,2}, and Shiqi Sun^{1*}

5 ¹ *State Key Laboratory of Animal Disease Control and Prevention, Lanzhou Veterinary Research*
6 *Institute, Chinese Academy of Agricultural Sciences, Lanzhou, China.*

7 ² *College of Veterinary Medicine, Gansu agricultural University, Lanzhou, Gansu, China.*

8 ³ *Lanzhou Institute of Biological Products Co., Ltd., Lanzhou 730046, China*

9 * Corresponding author at State Key Laboratory of Animal Disease Control and Prevention, Lanzhou
10 Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, China; E-mail
11 address: sunshiqi@caas.cn (Shiqi Sun).




Fig. S1 Characterization of the FMDV VLP mRNA Vaccine. (A) The changes in particle size and polydispersity index (PDI) of LNP-mP12A3C during storage at 4 °C were monitored over time; (B) Denaturing agarose gel electrophoresis of LNP-mP12A3C stored at 4 °C for up to 26 weeks; (C) Western blot analysis of LNP-mP12A3C stored at 4 °C for up to 26 weeks; (D): Denaturing and non-denaturing western blot analyses confirmed that transfection with LNP-mP12A3C successfully induced the expression of foot-and-mouth disease virus (FMDV)-specific structural proteins (VP0, VP1, and VP3), as well as their corresponding large molecular aggregates.




Fig. S2 Intracellular cytokine staining analysis of splenic lymphocytes from mice immunized with FMD VLP mRNA vaccine. (A-D) Flow cytometry analysis of IFN-γ-producing CD4⁺ (A) and CD8⁺ (C) T cells, and IL-2-producing CD4⁺ (B) and CD8⁺ (D) T cells.




Fig. S3 The long-term antibody levels induced by FMDV VLP mRNA Vaccine. (A) Specific antibody; (B) Neutralizing antibody titers.






Fig. S4 Immunofluorescence analysis of muscle tissue at the injection site and inguinal lymph node tissue in mice following immunization with FMD VLP mRNA vaccine. (A) Muscle tissue; (B) Inguinal lymph node tissue.




38 (B)



39

40

41 (C)



42

43 (D)




Fig. S5 Flow cytometry gating strategy. (A) Gating strategy for intracellular cytokine staining; (B) Gating strategy for TEM and TCM; (C) Gating strategy for Tfh; (D) Gating strategy for GCB.




Fig. S6 Gating strategy for flow-cytometric analysis of memory T-cell subsets and raw dot plots from individual mice in all experimental groups.

(A) Sequential gating strategy used to identify central memory T (Tcm, CD44⁺CD62L⁺) and effector memory T (Tem, CD44⁺CD62L⁻) cell subsets; (B) Raw dot plots of CD44 versus CD62L within gated CD4⁺ T cells from individual mice in the LNP and LNP-mP12A3C groups; (C) Raw dot plots of CD44 versus CD62L within gated CD8⁺ T cells from individual mice in the LNP and LNP-mP12A3C groups. The percentages shown in the plots represent the frequencies of Tcm or Tem cells in each individual mouse and correspond directly to the animal-level data used for quantification in Figure 3.




Fig. S7 Gating strategy for flow-cytometric analysis of germinal center B (GC B) cells and raw dot plots from individual mice in all experimental groups.

(A) Sequential gating strategy used to identify GC B cells (FAS⁺GL7⁺) within gated CD19⁺ B cells; (B) Raw dot plots of FAS versus GL7 within gated CD3⁻CD19⁺ cells from individual mice in the LNP and LNP-mP12A3C groups. The percentages shown in the plots represent the frequencies of GC B cells in each individual mouse and correspond directly to the animal-level data used for quantification in Figure 3.




Fig. S8 Gating strategy for flow-cytometric analysis of T follicular helper (Tfh) cells and raw dot plots from individual mice in all experimental groups.

(A) Sequential gating strategy used to identify Tfh cells (CXCR5⁺PD-1⁺) within gated CD3⁺CD4⁺ T cells; (B) Raw dot plots of CXCR5 versus PD-1 within gated CD3⁺CD4⁺ cells from individual mice in the LNP and LNP-mP12A3C groups. The percentages shown in the plots represent the frequencies of Tfh cells in each individual mouse and correspond directly to the animal-level data used for quantification in Figure 3.

The mRNA sequence of P12A3C(L127P) consists of the following elements:
5'UTR-P12A3C(L127P)-3'UTR-poly(A) tail.

TAATACGACTCACTATAATAAAAGATGGCGGATGTGTGACATACACGACGCCAAAAGATTTT
 GTTCCAGCTCCTGCCACCTCCGCTACGCGAGAGATTAACCAACCCACGACGGCCGCCAAAGT
 GCTTGTTGATATTGAGGCTGACAGCCCATTCATCAAGTCTTAGCAGAAGGCATTTCGTCGT
 TCGAGGTGGAGTCATTGGAGGTGACACCAAATCACCATCCAAATCCCAGAGCATTTTCGCA
 CCTGGGTACCAAATTGATCGAGCAGGAGACTGACAAAGACACACTCATCTTGGATCTAGTG
 CCACCATGGGCGCCGGCCAGAGCAGCCCCGCCACCGGCTCCCAGAACCAGTCCGGCAACA
 CCGGCTCCATCATCAACAATACTACTACATGCAGCAGTACCAGAACTCCATGGACACCCAGCT

83 GGGCAACAACGCCATCTCCGGCGGCTCCAACGAGGGCTCCACCGACACCACCTCCACCCA
84 CACCACCAACACCCAGAACAACGACTGGTTCTCCAAGCTGGCCTCCTCCGCCTTCTCCGGC
85 CTGTTTCGGAGCCCTGCTGGCCGACAAAAAGACCGAGGAGACCACACTGCTGGAAGACAG
86 AATCCTGACCACCAGAAACGGACACACCACCTCCACAACCCAGTCCTCCGTGGGCATCAC
87 CCACGGCTACGCCACCGCCGAGGACTTCGTGAACGGCCCCAACACCTCCGGCCTGGAGAC
88 CAGGGTGGTGCAGGCCGAGCGGTTCTTCAAGACCCACCTGTTGACTGGGTGACCTCCGA
89 CCCCTTCGGCCGGTACTACCTGCTGGAGCTGCCACCGACCACAAGGGCGTGTACGGCAGC
90 CTGACCGACTCCTACGCCTACATGCGGAACGGCTGGGACGTGGAGGTGACCGCCGTGGGC
91 AACCAGTTCAACGGCGGCTGCCTGCTGGTGGCCATGGTGCCCGAGCTGTGCTCCATCGAGC
92 AGAGGGAGCTGTTCCAGCTGACCCTGTTCCCCACCAAGTTCATCAACCCCCGGACCAACAT
93 GACCGCCACATCAAGGTGCCCTTCGTGGGCGTGAACAGGTACGACCAGTACAAGGTGCA
94 CAAGCCCTGGACCCTGGTGGTGATGGTGGTGGCCCCCTGACCGTGAACACCGAGGGCGC
95 CCCCCAGATCAAGGTGTACGCCAACATCGCCCCACCAACGTGCACGTGGCCGGCGAGTTC
96 CCCTCCAAGGAGGGCATCTTCCCCGTGGCCTGCTCCGACGGCTACGGCGGCCTGGTGACCA
97 CCGACCCCAAGACCGCCGACCCCGTGTACGGCAAGGTGTTCAACCCCCCGGAACATGC
98 TGCCCGGCAGGTTACCAACCTGCTGGACGTGGCCGAGGCCTGCCCCACCTTCCTGCACTT
99 CGACGGCGACGTGCCCTACGTGACCACCAAGACCGACTCCGACCGGGTGTGGCCAGTT
100 CGACCTGTCCCTGGCCGCCAAGCACATGTCCAACACCTTCCTGGCCGGCCTGGCCCAGTAT
101 TACACCCAGTACTCCGGCACCGTGAACCTGCACTTCATGTTACCGGCCCCACCGACGCCA
102 AGGCCCCGTACATGATCGCCTACGCCCCCCCCGGCATGGAGCCCCCAAGACCCCCGAGGC
103 CGCCGCCCACTGCATCCACGCCGAGTGGGACACCGGCCTGAACTCCAAGTTCACCTTCAGC
104 ATCCCCTACCTGTCCGCCGCCGACTACGCCTACACCGCCTCCGACGCCGCCGAGACCACCA
105 ACGTGCAGGGCTGGGTGTGCCTGTTCCAGATACCCACGGCAAGGCCGAGGGCGACGCC
106 TGGTGGTGTGCTGGCCTCCGCCGGCAAGGACTTCGAGCTGCGGCTGCCCCGTGGACGCCCGC
107 AGCAGACCACCTCCACCGGCGAGTCCGCCGACCCCGTGACCGCCACCGTGGAGAACTACG
108 GCGGCGAGACCCAGGTGCAGCGACGGCACACCGACGTGTCTTCATCCTGGACCGGT
109 TCGTGAAGGTGACCCCCAAGGACTCCATCAACGTGCTGGACCTGATGCAGACCCCCTCCCA
110 CACCCTGGTGGGCGCCCTGCTGCGGACCGCCACCTACTACTTCGCCGACCTGGAGGTGGCC
111 GTGAAGCACAAGGGCGACCTGACCTGGGTGCCAACGGCGCCCCCGTGGCCGCCCTGGAC
112 AACACCACCAACCCACCGCCTACCACAAGGCCCCCCTGACCCGGCTGGCCCTGCCCTACA
113 CCGCCCCCACCGGGTGTGGCCACCGTGTACAACGGCAAGTGCAAGTACGCCGAGGGCT
114 CCCTGCCCAACGTGCGGGGCGACCTGCAGGTGCTGGCCCAGAAGGCCGCCCGGCCCTGC
115 CCACCTCCTTCAACTACGGCGCCATCAAGGCCACCCGGGTGACCGAGCTGCTGTACCGGAT
116 GAAGCGGGCCGAGACCTACTGCCCCCGGCCCTGCTGGCCGTGCACCCCTCCGCCGCCG
117 GCACAAGCAGAAGATCGTGGCCCCCGTGAAGCAGAGCCTGAACTTCGACCTGCTGAAGCT
118 GGCCGGCGACGTGGAGTCCAACCCCGGCCCCAGCGGCCGCAGCGGCGCCCCCCCCGACCGA
119 CTTGCAGAAGATGGTCATGGGCAACACCAAGCCCGTGGAGCTCATACTCGACGGGAAGAC
120 CGTGGCCATCTGCTGCGCCACCGGCGTGTTCGGCACCGCCTACCTCGTGCCCCGGCACCTG
121 TTCGCCGAGAAGTACGACAAGATCATGTTGGACGGCAGGACCATGACCGACAGCGACTAC

[illegible]